Cargando…

Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report

Esophageal spindle cell carcinoma (ESpCC) is a rare subtype of esophageal carcinoma, accounting for 1% of all esophageal malignancies. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 60‐year‐old male with initially unresectable ESpCC, in which pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yang, Wang, Pei‐Pei, He, Du, Zheng, Yue, Ding, Zhen‐Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046125/ https://www.ncbi.nlm.nih.gov/pubmed/33619875 http://dx.doi.org/10.1111/1759-7714.13905

Ejemplares similares

Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols
por: Li, Chia-Ying, et al.
Publicado: (2016)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
por: Fu, Yang, et al.
Publicado: (2021)

Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report
por: Cao, Xiaomeng, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
por: Shen, Jianfei, et al.
Publicado: (2021)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Yang, Zhining, et al.
Publicado: (2019)

Dynamic (18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer
por: Chen, Zhi‐Yong, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
por: Zheng, Yue, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma
por: Tostes, Francinne T., et al.
Publicado: (2022)

IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma
por: Jiao, Ruidi, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer
por: Wong, Lye-Yeng, et al.
Publicado: (2023)

Prediction of pathological response grading for esophageal squamous carcinoma after neoadjuvant chemoradiotherapy based on MRI imaging using PDX
por: Shi, Jingzhen, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy
por: Guo, Hai, et al.
Publicado: (2023)

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

A three‐lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
por: Fu, Yang, et al.
Publicado: (2022)

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer
por: van Pelt, G.W., et al.
Publicado: (2019)

The predictive value of microRNAs for pathological response after neoadjuvant treatment in esophageal squamous cell carcinoma: a systematic review
por: Lin, Dong, et al.
Publicado: (2021)

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
por: Wu, Yingjia, et al.
Publicado: (2021)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer
por: Huang, Shu Jie, et al.
Publicado: (2022)

Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis
por: Chen, Yujia, et al.
Publicado: (2023)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis
por: Yu, Guocan, et al.
Publicado: (2021)

Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study
por: Hong, Zhinuan, et al.
Publicado: (2023)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma
por: Taghizadeh Kermani, Ali, et al.
Publicado: (2022)

Esophageal spindle cell lipoma
por: Val-Bernal, José-Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_74oqm70sf7cd2bl0u0e02p45nf